Stuart McGurnaghan
Overview
Explore the profile of Stuart McGurnaghan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hanlon P, Butterly E, Wei L, Wightman H, Almazam S, Alsallumi K, et al.
JAMA
. 2025 Feb;
PMID: 39899304
Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of...
2.
Lambourg E, Fu E, McGurnaghan S, Conway B, Dhaun N, Grant C, et al.
Am J Kidney Dis
. 2024 Nov;
85(2):196-204.e1.
PMID: 39521399
Rationale & Objective: Despite a lack of supporting evidence, current guidance recommends against the use of metformin in people with advanced kidney impairment. This observational study compared the outcomes of...
3.
Mellor J, Kuznetsov D, Heller S, Gall M, Rosilio M, Amiel S, et al.
Diabetologia
. 2024 Jul;
67(10):2210-2224.
PMID: 39037602
Aims/hypothesis: Whether hypoglycaemia increases the risk of other adverse outcomes in diabetes remains controversial, especially for hypoglycaemia episodes not requiring assistance from another person. An objective of the Hypoglycaemia REdefining...
4.
Mellor J, Kuznetsov D, Heller S, Gall M, Rosilio M, Amiel S, et al.
Diabetologia
. 2024 May;
67(8):1588-1601.
PMID: 38795153
Aims/hypothesis: The objective of the Hypoglycaemia REdefining SOLutions for better liVES (Hypo-RESOLVE) project is to use a dataset of pooled clinical trials across pharmaceutical and device companies in people with...
5.
Butterly E, Wei L, Adler A, Almazam S, Alsallumi K, Blackbourn L, et al.
BMJ Open
. 2022 Oct;
12(10):e066491.
PMID: 36302574
Introduction: Participants in randomised controlled trials (trials) are generally younger and healthier than many individuals encountered in clinical practice. Consequently, the applicability of trial findings is often uncertain. To address...
6.
Tomic D, Morton J, Chen L, Salim A, Gregg E, Pavkov M, et al.
Lancet Diabetes Endocrinol
. 2022 Oct;
10(11):795-803.
PMID: 36183736
Background: Diabetes is a major public health issue. Because lifetime risk, life expectancy, and years of life lost are meaningful metrics for clinical decision making, we aimed to estimate these...
7.
McKeigue P, McGurnaghan S, Blackbourn L, Bath L, McAllister D, Caparrotta T, et al.
Diabetes Care
. 2022 Jul;
46(5):921-928.
PMID: 35880797
Objective: Studies using claims databases reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection >30 days earlier was associated with an increase in the incidence of type 1 diabetes....
8.
McKeigue P, McAllister D, Caldwell D, Gribben C, Bishop J, McGurnaghan S, et al.
BMC Med
. 2021 Jun;
19(1):149.
PMID: 34158021
Background: Clinically vulnerable individuals have been advised to shield themselves during the COVID-19 epidemic. The objectives of this study were to investigate (1) the rate ratio of severe COVID-19 associated...
9.
Jeyam A, Colhoun H, McGurnaghan S, Blackbourn L, McDonald T, Palmer C, et al.
Diabetes Care
. 2021 Mar;
44(4):1072.
PMID: 33731365
No abstract available.
10.
Sidore C, Orru V, Cocco E, Steri M, Inshaw J, Pitzalis M, et al.
Mult Scler
. 2021 Feb;
27(9):1332-1340.
PMID: 33566725
Background: Defective alleles within the gene, encoding the pore-forming protein perforin, in combination with environmental factors, cause familial type 2 hemophagocytic lymphohistiocytosis (FHL2), a rare, severe autosomal recessive childhood disorder...